Achieve Life Sciences, Inc. (ACHV)

Latest News

View All News

May 13, 2025 7:30 AM EDT

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program View Press Release

May 6, 2025 8:30 am EDT

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025 11:19 am EDT

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 11, 2025 7:30 am EDT

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

View All News

Latest Presentation

Achieve Corporate Presentation 2025 View Presentation

View All Presentations

Upcoming Event

Jun 4, 2025 9:00 am PDT Annual Meeting of Stockholders View Event

Add to Calendar View All Events

Latest Financial Results

Q1 2025

Quarter Ended Mar 31, 2025

Earnings Release

Earnings Webcast

10-Q XBRL Zip

View All Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

View 10-K

Company Overview

Achieve Life Sciences is a specialty pharmaceutical company committed to addressing the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

View Management Team View Board of Directors

IR Contacts

Headquarters

Achieve Life Sciences, Inc.
22722 29th Dr. SE
Suite 100
Bothell, WA 98021
United States
T: 425-686-1500

Investor Relations

Nicole Jones
T: 425-686-1510
ir@achievelifesciences.com